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Levison, PHD, Zeneng Wang, PHD, Stanley L. Hazen, MD, PHD, W.H. Wilson Tang, MD
T he incidence of atherosclerotic coronary ar-tery disease (CAD), a common cardiovasculardisease (CVD), has been increasing and re-
mains a leading cause of death around the world
(1,2). Despite the considerable attention to traditional
risk factors (including age, sex, hypertension, dyslipi-
demia, smoking, and diabetes) and use of modern
pharmacotherapies, including high potency statin
therapy, at least a 50% residual risk remains (2–4).
Therefore, we are interested in identifying novel car-
diovascular risk factors to improve both our under-
standing of the processes that contribute to CVD
pathogenesis that have not been explained by tradi-
tional or known risk factors, and the prevention and
treatment of CVD (5).
There is growing appreciation that gut microbes
participate in the overall metabolism of their host,
and contribute to and are associated with car-
diometabolic disease phenotypes in both animal
models of disease and in humans (6–9). In particular,
a role for gut microbes as participants in the devel-
opment of atherosclerosis and CVD has recently
become acknowledged (10–12). Speciﬁcally, a gut mi-
crobial metabolite, trimethylamine N-oxide (TMAO),
has been shown to be atherogenic (12,13), and recent
studies that examined microbial transplantation in
recipients conﬁrmed a direct causal role for gut mi-
crobes in transmitting atherosclerosis susceptibility
and overall TMAO production (10). TMAO arises from
gut microbiota metabolism following ingestion of di-
ets rich in phosphatidylcholine (or lecithin), the ma-
jor dietary source of choline, and carnitine, an
abundant nutrient in red meat (11,12,14,15). Moreover,
elevated TMAO levels have been shown to predict a
future risk of major adverse cardiac events (MACE),
an increased prevalence of CVD, and have shown a
relationship with the number of diseased coronary
vessels (11,12,14). However, a relationship between
plasma TMAO levels and detailed characterization
and quantiﬁcation of atherosclerosis burden has not
been investigated.
The SYNTAX (Synergy Between Percutaneous
Coronary Intervention with Taxus and Cardiac Sur-
gery) trial produced the SYNTAX score, which is an
angiographic scoring system to determine the
complexity and burden of atherosclerotic CAD (16,17).
The anatomical SYNTAX score has been shown to
predict MACE and long-term prognosis risks among
stable patients with CAD who have undergone coro-
nary revascularization (18,19). However, due to some
limitations of this score, including lack of clinical
variables and a purely anatomical focus, the SYNTAX
score II was recently developed, with a
presumed improved prognostic value. It
consists of a combination of 2 anatomical
(SYNTAX score and unprotected left main
CAD) and 6 clinical variables (age, creatinine
clearance, left ventricular ejection fraction,
sex, chronic obstructive pulmonary disease,
and peripheral artery disease [PAD]). The
SYNTAX score II has shown better long-term
(4-year) mortality prediction between coro-
nary artery bypass graft (CABG) surgery and
percutaneous coronary intervention (PCI)
than the original SYNTAX score (20). Patients
with diffuse lesions present a higher risk for
an adverse outcome after coronary revascu-
larization due to a higher incidence of reste-
nosis, poor run-off in the target CABG, and an
increased risk of adverse cardiovascular out-
comes (21–23).
In this study, we aimed to examine the
relationships between plasma TMAO levels
and coronary artery atherosclerotic lesion
complexity and burden quantiﬁed by SYN-
TAX scores and lesion characteristics.
METHODS
This is a single-center prospective cohort
study approved by the Cleveland Clinic
Institutional Review Board. All subjects pro-
vided written informed consent.
From the total of 989 patients who underwent
elective diagnostic cardiac catheterization at the
Cleveland Clinic between 2012 and 2014 who did
not have evidence of acute coronary syndrome
(cardiac troponin T level: <0.03 mg/l), we speciﬁcally
excluded patients with a history of cardiac trans-
plantation, PCI, CABG, and who had undergone a
noncoronary artery procedure (structural heart pro-
cedure or for PAD), and patients who had no evidence
of signiﬁcant CAD (total exclusion: 636 patients)
(Figure 1). Therefore, 353 consecutive patients with
evidence of signiﬁcant CAD, deﬁned by a diameter
stenosis of $50% in vessels $1.5 mm, were included
in this study.
ANGIOGRAPHIC ANALYSIS. Images of coronary
angiograms were obtained with Syngo Dynamics
cardiovascular imaging software (Siemens Medical
Solutions USA, Inc., Malvern, Pennsylvania). The
SYNTAX score was calculated for each patient using a
computer program that consisted of sequential and
interactive self-guided questions according to the
SYNTAX score calculator version 2.11, and divided
into tertiles according to the SYNTAX trial, which
AB BR E V I A T I ON S
AND ACRONYM S
AUC = area under the receiver-
operating curve
BMI = body mass index
CABG = coronary artery bypass
graft
CAD = coronary artery disease
CI = conﬁdence interval
CVD = cardiovascular disease






MACE = major adverse cardiac
events
NRI = net reclassiﬁcation index
OR = odds ratio
PAD = peripheral arterial
disease
PCI = percutaneous coronary
intervention
SYNTAX score = Synergy
Between Percutaneous
Coronary Intervention with




were deﬁned as low (0 to 22), intermediate (23 to 32),
and high ($33) SYNTAX scores. The SYNTAX score II
was calculated for each patient using a nomogram
and stratiﬁed according to tertiles of SYNTAX score II
for PCI as previously described (20,24). A diffuse
lesion was deﬁned as de novo CAD of >75% of the
length of any segment(s) proximal to the lesion, at the
site of the lesion, or distal to the lesion that had a
vessel diameter of <2.0 mm; it was considered non-
diffuse if the arteries contained no such lesion (25).
A focal lesion was deﬁned as de novo CAD of >50%
reduction in luminal diameter and a lesion length
of <20.0 mm. We indicated diffuse lesions if at least 1
diffuse lesion characteristic was present, focal lesions
if pure focal lesions were present, and nondiffuse and
nonfocal lesions if they did not meet the criteria for
those lesions. All angiograms were reviewed by an
interventional cardiologist who was blinded to TMAO
level and clinical variable data.
LABORATORY TESTING. After informed consent was
obtained from all patients, fasting blood samples
were collected using ethylenediaminetetraacetic acid
FIGURE 1 CONSORT (Consolidated Standards of Reporting Trials) Diagram
989 consenting patients who underwent elective
diagnostic cardiac catheterization at the Cleveland Clinic between
2012 and 2014
561 patients excluded because of prior
history of cardiac transplant (107),
prior CABG (137), prior PCI (79) and
non-coronary procedure (238)
(transcatheter valve implantation=30, PAD=208)
428 patients underwent angiographic analysis
75 patients excluded because no
evidence of significant CAD
Final: 353 patients included analyzed
289, 40, and 24 patients had low,
intermediate, and high anatomical
SYNTAX score, respectively
73, 193, and 87 patients had diffuse, focal,
and not met criteria for diffuse and focal
lesion, respectively
The ﬂow diagram showing the process used to deﬁne the study population is depicted. CABG coronary artery bypass surgery; CAD coronary
artery disease; PAD peripheral artery disease; PCI percutaneous coronary intervention; SYNTAX Synergy Between Percutaneous Coronary
Intervention with Taxus and Cardiac Surgery.
and SYNTAX score II (>21) and adjusted for the same
covariates from the regression model with traditional
risk factors, lesion characteristic, hsCRP, eGFR,
BMI, and medications (27). All analyses were per-
formed using JMP Pro version 10 (SAS Institute,
Cary, North Carolina) and R (version 3.1.2, Vienna,
Austria). A p value <0.05 was considered statistically
signiﬁcant.
RESULTS
PATIENT CHARACTERISTICS. Baseline characteris-
tics of the 353 patients included in our study are
shown in Table 1. The mean age was 65 years of age,
79% were men, 80% had hypertension, and 30% had
diabetes. The median TMAO was 5.48 mM (IQR: 3.41 to
9.76 mM), the median SYNTAX score was 11.0
(IQR: 4.0 to 18.5), and 289 (82%), 40 (11.3%), and 24
(6.8%) patients had low, intermediate, and high
SYNTAX scores, respectively. The baseline charac-
teristics according to SYNTAX score tertiles showed
that a patient with a higher SYNTAX score was more
likely to be older and have hypertension and dia-
betes. In contrast, sex, a history of smoking, and
BMI were similar across SYNTAX score tertiles
(Table 1). TMAO levels were signiﬁcantly higher with
an increasing SYNTAX score, SYNTAX score II, and
hs-cTnT tertiles (Central Illustration).
CORRELATIONS WITH PLASMA TMAO LEVELS. Plasma
TMAO levels were strongly correlated with both
SYNTAX score and SYNTAX score II (Spearman’s
correlation: r 0.61 and 0.62, respectively; both
p < 0.0001). Plasma TMAO was also correlated with
hs-cTnT, a measure of subclinical myonecrosis,
because all hs-cTnT levels were below the diagno-
stic cutoff for myocardial infarction (r 0.29;
p < 0.0001). Following ordinal logistic regression
analysis adjusting for traditional risk factors
(including age, sex, hypertension, diabetes mellitus,
smoking, low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, and triglyceride)
and lesion characteristics, elevated TMAO levels
remained independently associated with a higher
tertile of the SYNTAX score (adjusted odds ratio [OR]:
4.68; 95% conﬁdence interval [CI]: 2.35 to 9.29;
p < 0.0001), SYNTAX score II (adjusted OR: 2.02;
95% CI: 1.72 to 3.01; p 0.0001), and hs-cTnT (adjusted
OR: 1.34; 95% CI: 1.02 to 1.78; p 0.037). However,
when further adjusted for hsCRP, BMI, eGFR, and
medications, the association between TMAO and
hs-cTnT was no longer signiﬁcant, whereas SYNTAX
score and SYNTAX score II remained signiﬁcant
(Table 2).
tubes? at? the? time? of? cardiac? catheterization,? which?
were?then? immediately?processed?and?frozen?at? 80C?
until?analysis.?TMAO?levels?in?plasma?were?determined?
using? stable? isotope? dilution? high-performance? liquid?
chromatography? with? online? tandem? mass?
spectrometry? on? an?API? 5000? triple? quadrupole?mass?
spectrometer? (AB? SCIEX,? Framing-ham,?
Massachusetts),? as? previously? described? (12,26).? The?
assay? shows? inter-? and? intraday? reproducibility? (all?
coefﬁcient? of? variations? <7%)? and? accuracy? (>98.5%?
across? low,?mid,? and?high?values).?Routine? laboratory?
tests? and? high-sensitivity? C-reactive? pro-tein? (hsCRP)?
were? measured? using? the? Architect? ci8200? platform?
(Abbott? Laboratories,?Abbott? Park,? Illinois),? and? high-
sensitivity?cardiac?troponin?T? (hs-cTnT)?was?measured?
by? a? high-sensitivity? (ﬁfth? generation)? assay? on? a?
Roche? Cobas? e411? platform? (Roche? Diagnostics,?
Indianapolis,? Indiana).?Estimated?glomerular?ﬁltration?
rate? (eGFR)?was? esti-mated? using? the?Modiﬁcation? of?
Diet?in?Renal?Disease?equation.
STATISTICAL ? ANALYSIS. ? Continuous? data? are? pre-
sented? as?mean? ? SD? or?median? (interquartile? range?
[IQR]) ? and compared with the ? Student ? t?test?
or? nonparametric? test? when? appropriate.? Categorical?
variables? are? presented? as? number? (percent)? and?
compared? between? groups? with? chi-square? tests.?
Spearman? correlation? analysis? was? used? to? examine?
the? associations? between? TMAO? and? all? clinical? and?
laboratory? variables.? Comparisons? among? $3 groups?
were? evaluated? by? 1-way? analysis? of? variance? or? the?
Kruskal-Wallis? test? according? to? whether? or? not? the?
distribution? was? normal.? Ordinal? logistic? regression?
analysis,? adjusted? for? traditional? Framingham? risk?
factors? (including? age,? sex,? hypertension,? diabetes?
mellitus,? smoking,? low-density? lipoprotein? choles-
terol,? high-density? lipoprotein? cholesterol,? and? tri-
glycerides),? lesion? characteristics,?hsCRP,? eGFR,?body?
mass? index? (BMI),? and? medications? (angiotensin-
converting? enzyme? inhibitor/angiotensin? receptor?
blocker,?beta-blockers,?statins,?and?aspirin)?were?used?
to? examine? the? association? of? TMAO? with? higher?
SYNTAX?score,?SYNTAX?score? II,?and?hs-cTnT? tertiles.?
Univariate? and? multivariate? logistic? regression? ana-
lyses?were?used? to?determine? independent?predictors?
of?diffuse?or?focal? lesions;?the?variables?were?en-tered?
into? the? model,? including? the? previously? mentioned?
traditional?risk? factors?and?hs-cTnT? (log-transformed).?
Category-free? net? reclassiﬁcation? indexes? (NRI)? and?
area?under?the?receiver-operating?characteristic?curves?




with stable CAD who underwent elective coronary
angiography (28), although renal insufﬁciency could
be a confounder. Furthermore, elevated TMAO
levels were found to serve as an independent
predictor of higher SYNTAX score, higher SYNTAX
score II, and elevated hs-cTnT, even after adjust-
ments for traditional risk factors and lesion charac-
teristics on coronary artery angiography. A higher
plasma TMAO level was also shown to serve as an
independent predictor for the presence of
CENTRAL ILLUSTRATION Relationship Between TMAO and Measures of CAD Burden and Subclinical Myonecrosis
Senthong, V. et al. J Am Coll Cardiol. 2016;67(22):2620 8.
Trimethylamine N oxide (TMAO) has links to coronary artery disease (CAD) pathogenesis and is associated with adverse outcomes. One way to measure CAD complexity
and burden is via the SYNTAX score that came from the SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial; the more
recent SYNTAX score II has been shown to have improved prognostic ability. In 353 stable patients with evidence of atherosclerotic CAD, concentrations of TMAO
were signiﬁcantly higher with (A) increasing SYNTAX score, (B) SYNTAX score II, and (C) subclinical myonecrosis (quantiﬁed by high sensitivity cardiac troponin
T [hs cTnT]) tertiles. PCI percutaneous coronary intervention.

Furthermore, results from recent studies in mice fed a
high-fat diet also suggest that dietary TMAO may
exacerbate impaired glucose tolerance, obstruct
hepatic insulin signaling, and promote adipose tissue
inﬂammation, which have been related to the
complexity and degree of atherosclerotic burden of
CAD (38). It is also of interest that recent studies have
further implicated ﬂavin monooxygenase 3 in
atherosclerosis development in rodent models of
diabetes (39).
STUDY LIMITATIONS. This was a single, tertiary
referral center that recruited patients at the point of
cardiac evaluation; therefore, we could not exclude
selection bias for patients who underwent diagnostic
cardiac catheterization (especially with relatively
preserved renal function). Because the patient
populationwas a contemporary cohort (the last patient
was enrolled in 2014), we did not have long-term
outcome data. Despite all subjects being recruited at
the time of coronary angiography while fasting for at
least 10 h in anticipation of coronary angiography, we
could not exclude the potential for dietary intake of
choline or TMAO (e.g., large consumption of some ﬁsh
species) within 24 h before blood sampling. The rela-
tively low number of the patients in the intermediate
and high SYNTAX score tertiles was a also limitation of
our study. Furthermore, improvement in AUC for a
model is often very small in magnitude, yet the
category-free NRI may tend to overstate the incre-
mental value of a biomarker.
CONCLUSIONS
Fasting plasma TMAO level is an independent pre-
dictor of high atherosclerotic burden in patients with
CAD. Higher TMAO levels can predict the presence of
increased atherosclerotic burden and complexity, as
evidenced by higher SYNTAX scores and diffuse
lesion characteristics. Despite the associative nature
in this cross-sectional study, these ﬁndings are
consistent with numerous previous mechanistic
demonstrations that have linked TMAO to the path-
ogenesis of atherosclerosis, and the multiple reported
ﬁndings that have demonstrated associations be-
tween TMAO and cardiovascular risks. Further in-
vestigations into the mechanisms of elevated TMAO
leading to atherosclerotic burden and myonecrosis
are warranted.
by showing striking and independent associations 
between TMAO and enhanced coronary artery 
atherosclerotic burden. Thus, the results are consis-
tent with the gut microbial TMAO pathway being 
mechanistically linked with the development of CAD 
and the pathogenesis of CVD (12–14,35).
Previous studies showed that the SYNTAX 
score is a useful tool to risk stratify outcomes in 
stable patients with complex CAD (with or without 
unprotected left main CAD) who have undergone 
revascularization by PCI or CABG. These studies 
independently predicted MACE and all-cause 
mortality, which increased in the higher SYNTAX 
score tertiles (18,19). A high SYNTAX score is 
also a marker of systemic atherosclerotic burden, 
which likely correlates with a poor prognosis (16,17).
In our study, plasma TMAO levels were correlated 
with both the SYNTAX score (anatomical factors) and 
the SYNTAX score II (both anatomical and clinical 
factors). We also found elevated plasma TMAO to be an 
independent predictor for the presence of diffuse lesion 
characteristics, which represent markers of higher 
atherosclerotic burden and are associated with adverse 
outcomes in CAD (22,36). In contrast,  elevated 
plasma TMAO levels showed an inverse and 
independent association with the presence of focal 
lesions, which indicates a lower atherosclerotic burden. 
Importantly, despite the present study cohort including 
stable subjects without evidence of acute coronary 
syndrome (cardiac troponin T level, <0.03 mg/l) at 
presentation, elevated plasma TMAO was associated 
with evidence of subclinical myonecrosis, as indicated 
by a higher level of hs-cTnT. It is thus conceivable that 
subclinical myo-necrosis or high severity and an 
atherosclerotic burden of CAD may occur in the setting 
of elevated plasma TMAO levels. Taken together, our 
current ﬁndings provided the additional support for a 
pro-atherogenic effect of elevated systemic levels of 
TMAO. The mechanism of the relation between plasma 
TMAO and atherosclerotic burden might be explained 
by our previous studies that showed that higher plasma 
TMAO was correlated with greater atherosclerotic 
plaque size in both the arterial wall and aortic root in 
mice on diets supplemented with either TMAO or 
choline (12). TMAO may  have  direct  biological 
activity that facilitates the development or propagation 
of atherosclerosis plaque and suppres-sion of reverse 
cholesterol transport in in vivo mouse models (12,13). 
Moreover, recent studies suggest that ﬂavin 
monooxygenase 3, the major host enzyme responsible 
for forming TMAO from gut microbe–generated 
trimethylamine, is a master regulator of tissue 
cholesterol and sterol metabolism (37).
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The in-
testinal microbe-generated phosphatidylcholine metab-
olite TMAO is related to the pathogenesis of
atherosclerotic CAD.
TRANSLATIONAL OUTLOOK: Further research is
needed to determine whether dietary or pharmacological
interventions that reduce plasma levels of TMAO can pre-
vent or retard the progression of coronary atherosclerosis.
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